Cordis/Volcano
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis will promote Volcano's intravascular ultrasound technology alongside its Cypher drug-eluting stents in Europe under a non-exclusive collaboration announced Nov. 8. Currently, only 3.5% of percutaneous coronary interventions performed in Europe use IVUS imaging technology to guide stent placement. Volcano and Johnson & Johnson are also both cosponsors of the ADAPT-DES study, which will enroll from 11,000 to 15,000 patients, including 3,000 patients who will be imaged with Volcano's Eagle Eye Gold IVUS catheter during initial drug-eluting stent placement and in follow-up assessments of dual antiplatelet therapy (1"The Gray Sheet" Oct. 29, 2007, p. 8)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.